glp-1 drugs for parkinson's disease does not slow progression in phase 3 study GLP-1 Signalling as a Therapeutic

The only trouble is, despite the clever marketing, theyre not actually a solution for sustainable weight loss. Its unsurprising that brands are jostling to fill the gap created by Ozempic as the shift to thin gains momentum and there is huge money to be made

Whilst one meta-analysis of five RCTs found no significant improvements in any of the BD scores, 81 another meta-analysis of six studies found a significant effect of NAC on Clinical Global Impression-Severity Scale (CGI-S) score, but not any other scores

With respect to desensitization, all those data support the idea that agonists are able to promote a different regulation of OR as demonstrated for other GPCR such as the histamine H2 receptors (Alonso et al., 2014)

(PubMed) Brevetti G, Diehm C, Lambert D

Inflammation Modulation Investigated for its potential to reduce inflammation in various tissue injury models